Immunome (IMNM) Cash from Financing Activities (2019 - 2026)
Immunome (IMNM) posted Cash from Financing Activities of -$135000.0 for Q1 2026, down 100.03% on a QoQ basis from $432.8 million in Q4 2025, and down 100.08% year-over-year from $162.2 million in Q1 2025.
Immunome (IMNM) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Immunome's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$135000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 100.08% year-over-year to -$135000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $478.0 million (up 160.75% YoY) and the FY2025 annual result came in at $640.4 million, up 166.23% from the prior year.
- Cash from Financing Activities was -$135000.0 for Q1 2026 at Immunome, down from $432.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $432.8 million in Q4 2025 and bottomed at -$135000.0 in Q1 2026.
- A 5-year average of $76.7 million and a median of $20.1 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 645326.47% — and 2025, when it slumped 107.93%.
- Immunome's Cash from Financing Activities stood at $32000.0 in 2022, then soared by 173334.38% to $55.5 million in 2023, then sank by 63.81% to $20.1 million in 2024, then jumped by 2054.82% to $432.8 million in 2025, then slumped by 100.03% to -$135000.0 in 2026.
- Business Quant data shows IMNM's Cash from Financing Activities at -$135000.0 in Q1 2026, $432.8 million in Q4 2025, and $45.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Immunome | 2.49 Bn | 1.91 Bn | - | -135,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -135,000.00 |
| Mar 31, 2026 | -135,000.00 |
| Dec 31, 2025 | 432.80 Mn |
| Dec 31, 2025 | 432.80 Mn |
| Sep 30, 2025 | 45.39 Mn |
| Sep 30, 2025 | 45.39 Mn |
| Jun 30, 2025 | -55,000.00 |
| Jun 30, 2025 | -55,000.00 |
| Mar 31, 2025 | 162.23 Mn |
| Mar 31, 2025 | 162.23 Mn |
| Dec 31, 2024 | 20.09 Mn |
| Dec 31, 2024 | 20.09 Mn |
| Sep 30, 2024 | 305,000.00 |
| Sep 30, 2024 | 305,000.00 |
| Jun 30, 2024 | 694,000.00 |
| Jun 30, 2024 | 694,000.00 |
| Mar 31, 2024 | 219.45 Mn |
| Mar 31, 2024 | 219.45 Mn |
| Dec 31, 2023 | 55.50 Mn |
| Dec 31, 2023 | 55.50 Mn |